Open in interactive viewer → charts, metric popovers & call review

Verrica Swaps the Wart Story for a Rare Disease It Hasn't Begun to Study

Record YCANTH revenue masked by applicator decline; a brand-new Gorlin syndrome narrative lands on a stock down 43% in 90 days
VRCA · Earnings Call · 2026-11-12

The Tape Voted First, and It Voted No

Verrica walked into Wednesday's call with a 90-day return of -43%, a one-way slide from $6.26 on July 10 to under $4, on a $61.6 million market cap and 98% below its 2018 peak of $203.40. That is not the tape of a company being graded on molluscum demand. It is the tape of a company being graded on cash, dilution, and the length of the wait. Which makes the call's opening framing — “record YCANTH revenue for the second quarter in a row” — Jayson Rieger, President and Chief Executive Officer · 2026-11-12 — technically true and strategically beside the point. The real news on this call was not revenue. It was a vocabulary swap.

Revenue Up, Applicators Down: The Yield Trade Arrives

U.S. net YCANTH product revenue was $5.7 million against $3.6 million a year ago, and gross product margin jumped to 89.8% from 79.1%. But dispensed applicator units were 19,135 — down 491 sequentially, up 35.8% year over year. Revenue rose roughly 11.9% while volume fell. That divergence is the entire quarter. Management's explanation is a gross-to-net fix: steered fulfillment. Chris Chapman described it plainly —

what you're seeing a reflection of in that accretion of yield is directing medical benefit claims into in-network pharmacies who are capable of submitting that claim and getting reimbursement

Chris Chapman, Unknown - likely Commercial or Sales Executive · 2026-11-12
— with roughly a 50/50 medical-versus-pharmacy benefit split and, by his account, many medical claims clearing with no prior authorization. Two analysts independently probed whether this is durable or a one-time capture, which is the right question. It is also a promise being kept: last quarter Chapman said “we fully expect to see yield to continue to accrete over time” — Chris Chapman, Unknown · 2026-08-06. One quarter of delivery does not make a trend, and the keyword tape reflected the ambiguity — net YCANTH revenue actually lost momentum this quarter even as the dollar figure set a record. The optics get worse at the total line, where reported revenue of $6.9 million was up 17% sequentially but down 54% year over year because the prior-year quarter carried a one-time $10 million Torii milestone. That base effect now rolls off permanently: licensing collaboration revenue was $1.2 million, and CFO John Kirby was explicit that “the revenue will be similar, but probably a little less” — John Kirby, Interim Chief Financial Officer · 2026-11-12 as Japan shifts to ampoule supply and then royalties. Japan goes from revenue line to footnote.

Gorlin Syndrome: A Brand-New Word, Announced Before It Exists

The cleanest signal in this dataset is lexical. Last quarter Verrica's keyword top-30 was dominated by the credit facility, the COVE-2 and COVE-3 wart trials, the field force, and unit-versus-revenue growth. Almost all of that is gone. In its place: Gorlin syndrome and Gorlin patients at the very top, followed by sporadic BCC, abscopal effect, hedgehog inhibitors, and study design. Essentially none of this cluster existed for this company a quarter ago. It is company-unique — no global theme, no other reporter in the recent batch shares it. That cuts both ways: it is genuinely new information, and it is genuinely unvalidated. The clinical logic is decent. Gorlin patients develop dozens to hundreds of basal cell carcinomas and face a lifetime of excisions; prevalence is roughly 11,000 in the U.S.; there is no approved therapy. Verrica's Phase II in sporadic BCC showed a 97% objective response rate, an average 86% tumor-size reduction, and untreated lesions shrinking 67% on average. That last number is why the abscopal effect keeps showing up in the lexicon. Here is the tension. The FDA, per management, asked Verrica to include Gorlin patients in the already-aligned Phase III protocol. Verrica is instead going to run a separate open-label proof of concept first — "exploring," "finalizing study design," with no protocol, no budget, and no timeline. Thomas Flaten pushed on this twice, and Jayson Rieger's answer is the most revealing sentence of the call: “we wouldn't want to do that without having had some data in that population on the off chance that we're not correct” — Jayson Rieger, President and Chief Executive Officer · 2026-11-12 — followed shortly by “You don't necessarily need to complete the entire study to initiate the Phase III.” — Jayson Rieger, President and Chief Executive Officer · 2026-11-12 Read together: an unspecified delay to a pivotal program, in exchange for optionality nobody can underwrite yet.

What Fell Silent: The Warts, and the Balance Sheet

COVE-2 is fully enrolled with top-line data expected in the first quarter of 2027; COVE-3 is past 50% enrollment, data by mid-2027. Both facts were stated and then dropped. The COVE keywords that ranked third and fourth last quarter are absent from this quarter's top 30 entirely. That is what a settled question looks like — and also what five months of dead air looks like. The label expansion into a multibillion dollar common-warts market (22 million U.S. patients, zero approved therapies) remains the whole equity story, and the next checkpoint is far enough away that the intervening quarters will be traded on financing risk. Which is why the quietest story matters. The credit facility with an entity controlled by chairman Paul Manning — up to $27.5 million — had its remaining $15 million unlocked in late October on operational and performance milestones. Yet the credit facility itself fell out of the company's own top-30 keyword set, even though it is arguably the single most important fact disclosed. Last quarter Kirby said “we will be selective and strategic and only draw as much as we need when we need it” — John Kirby, Interim Chief Financial Officer · 2026-08-06; this quarter the gate was cleared and $14.4 million of cash plus full draw now funds operations past both wart readouts, into the fourth quarter of 2027. The cost of that comfort is a 16% IRR catch-up to the lender on repayment. Meanwhile the expense line looks alarming and mostly isn't: R&D expense of $7.6 million, up from $2.2 million, of which $5.2 million was non-cash because Torii funds the first $40 million of the wart program, roughly 90% of the budget. Burn is the honest number: free cash flow less stock-based compensation of roughly -$9 million in the June quarter, with a net loss of $12.4 million, or $0.58 per share, this quarter. So the story is this: the commercial engine is finally squeezing more dollars out of fewer prescriptions, the wart program is fully funded and fully dormant until February, and management has opened a new, emotionally compelling — and completely unscoped — front in a rare disease that the FDA never demanded. The competitive framing hasn't changed in a year; Rieger was saying in November 2025 that “we continue to view the largest competitor to the treatment of molluscum as being watch and wait” — Jayson Rieger, President and Chief Executive Officer · 2025-11-17, and watchful waiting remains the named enemy. What changed is that the growth drivers now have to carry the entire narrative for two more quarters while a 43% drawdown does the talking.